BRAF and thyroid gland carcinoma: Multikinase inhibitors, such as sorafenib and lenvatinib, have been used successfully to treat thyroid carcinoma (6, 7), and specific inhibitors for genetic abnormalities acquired early, such as BRAF, RET, and NTRK alterations, are effective (8-12).